Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma

Oncology (Switzerland)

Volumn 90, Issue 3, 2016, Pages 167-175

  Kunimoto, Hideo ^a   Ikeda, Kenji ^a   Sorin, Yushi ^a   Fujiyama, Shunichiro ^a   Kawamura, Yusuke ^a   Kobayashi, Masahiro ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Akuta, Norio ^a   Saitoh, Satoshi ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Carcinogenesis; Hepatitis C; Hepatocellular carcinoma; Recurrence rate; Survival rate; Sustained virological response

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER RESECTION; MALE; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; SURVIVAL RATE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DRUG EFFECTS; HEPATITIS C, CHRONIC; INCIDENCE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; TUMOR RECURRENCE; VERY ELDERLY; VIROLOGY; VIRUS LOAD;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RIBAVIRIN; VIRAL LOAD;

EID: 84959183007     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000443891     Document Type: Article

References (25)

1. Lok AS: Chronic hepatitis B. N Engl J Med 2002; 346: 1682-1683.
2. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002; 36(5 suppl 1):S35-S46.
3. Tanaka J, Kumada H, Ikeda K, Chayama K, Mizui M, Hino K, Katayama K, Kumagai J, Komiya Y, Miyakawa Y, Yoshizawa H: Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 2003; 70: 378-386.
4. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2, 215 patients. J Hepatol 1998; 28: 930-938.
5. McGivern DR, Lemon SM: Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011; 30: 1969-1983.
6. Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N: α-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58: 1253-1262.
7. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK: Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-199.
8. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; HALT-C Trial Group: Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-844.
9. Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H: Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005; 40: 148-156.
10. Hirakawa M, Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Kumada H: Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med 2008; 47: 1637-1643.
11. Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K: Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol 2011; 46: 799-808.
12. Sato A, Sata M, Ikeda K, Kumada T, Izumi N, Asahina Y, Osaki Y, Chayama K, Kaneko S, Sakai A, Onji M, Hiasa Y, Omura T, Ozeki I, Yokosuka O, Shiina S, Itsubo M, Nishiguchi S, Hirano K, Ide T, Sakisaka S, Yamasaki T, Hidaka I, Tanaka M, Kim SR, Ichida T: Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. Intern Med 2013; 52: 2701-2706.
13. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL; Italian Association of the Study of the Liver Disease (AISF): Sustained virological response to interferon-Alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007; 45: 579-587.
14. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-Term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130.
15. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y: Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-Analysis of observational studies. Ann Intern Med 2013; 158(5 Pt 1):329-337.
16. Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, Shiga J, Takikawa H: Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13: 5180-5187.
17. Iino S: Relationship between infection with hepatitis C virus and hepatocellular carcinoma in Japan. Antivir Ther 1998; 3(suppl 3):143-146.
18. Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Ito T: Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol 2015; 30: 1183-1189.
19. Sato A, Sata M, Ikeda K, Kumada T, Izumi N, Asahina Y, Osaki Y, Chayama K, Kaneko S, Sakai A, Onji M, Hiasa Y, Omura T, Ozeki I, Yokosuka O, Shiina S, Itsubo M, Nishiguchi S, Hirano K, Ide T, Sakisaka S, Yamasaki T, Hidaka I, Tanaka M, Kim SR, Ichida T: Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. Intern Med 2013; 52: 2701-2706.
20. Tachi Y, et al: Predictive ability of laboratory indices for liver fibrosis in patients with chronic hepatitis C after the eradication of hepatitis C virus. PLoS One 2015; 10:e0133515.
21. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
22. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-1801.
23. Singal AK, Freeman DH Jr, Anand BS: Metaanalysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 32: 851-858.
24. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-232.
25. Shiratori Y, lmazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann lntern Med 2000; 132: 517-524.